About this Journal Submit a Manuscript Table of Contents
Advances in Preventive Medicine
Volume 2012 (2012), Article ID 149737, 4 pages
http://dx.doi.org/10.1155/2012/149737
Review Article

The Need for Continued Development of Ricin Countermeasures

1Division of Clinical Medicine, Clinical Research Management Inc., Team Ke’aki Tech, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702-5011, USA
2Division of Toxinology, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702-5011, USA

Received 1 August 2011; Accepted 10 January 2012

Academic Editor: Phillip R. Pittman

Copyright © 2012 Ronald B. Reisler and Leonard A. Smith. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. A. Balint, “Ricin: the toxic protein of castor oil seeds,” Toxicology, vol. 2, no. 1, pp. 77–102, 1974. View at Publisher · View at Google Scholar · View at Scopus
  2. Centers for Disease Control and Prevention, “Biological and chemical terrorism: strategic plan for preparedness and response,” Morbidity and Mortality Weekly Report, vol. 49, no. RR-4, pp. 1–14, 2000.
  3. J. Cookson and J. Nottingham, A Survey of Chemical and Biological Warfare, vol. 6, Monthly Review Press, New York, NY, USA, 1969.
  4. M. A. Poli, C. Roy, K. D. Huebner, D. R. Franz, and N. K. Jaax, “Ricin,” in Medical Aspects of Biological Warfare, Z. F. Dembek, Ed., pp. 323–335, Borden Institute, Washington, DC, USA, 2007.
  5. J. Audi, M. Belson, M. Patel, J. Schier, and J. Osterloh, “Ricin poisoning a comprehensive review,” Journal of the American Medical Association, vol. 294, no. 18, pp. 2342–2351, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. K. S. Eiklid, S. Olsnes, and A. Pihl, “Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells,” Experimental Cell Research, vol. 126, no. 2, pp. 321–326, 1980. View at Scopus
  7. A. M. Soler-Rodriguez, J. W. Uhr, J. Richardson, and E. S. Vitetta, “The toxicity of chemically deglycosylated ricin A-chain in mice,” International Journal of Immunopharmacology, vol. 14, no. 2, pp. 281–291, 1992. View at Scopus
  8. V. Radosavljevic and G. Belojevic, “A new model of bioterrorism risk assessment,” Biosecurity and Bioterrorism, vol. 7, no. 4, pp. 443–451, 2009. View at Publisher · View at Google Scholar
  9. L. J. Schep, W. A. Temple, G. A. Butt, and M. D. Beasley, “Ricin as a weapon of mass terror—separating fact from fiction,” Environment International, vol. 35, no. 8, pp. 1267–1271, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. W. T. Porter, An Introduction to Physiology, The University Press, Cambridge, Mass, USA, 1906.
  11. A. C. Cope, Ricin in Summary Technical Report of Division 9 on Chemical Warfare and Related Problems, chapter 12, Office of Scientific Research and Development, Washington, DC, USA, 1946, Parts I–II. National Defense Research Committee.
  12. M. A. Poli, V. R. Rivera, M. L. M. Pitt, and P. Vogel, “Aerosolized specific antibody protects mice from lung injury associated with aerosolized ricin exposure,” Toxicon, vol. 33, p. 289, 1996.
  13. M. A. Poli, V. R. Rivera, M. L. M. Pitt, and P. Vogel, “Aerosolized specific antibody protects mice from lung injury associated with aerosolized ricin exposure,” Toxicon, vol. 34, no. 9, pp. 1037–1044, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. P. V. Lemley, P. Amanatides, D. Creasia, J. Ruvo, A. O’Neill, and D. C. Stafford, “Chicken antitoxin neutralizes ricin in vitro and in vivo,” Toxicon, vol. 31, p. 527, 1993.
  15. P. V. Lemley and D. C. Wright, “Active immunization after passive monoclonal antibody and ricin toxin challenge,” Toxicon, vol. 30, p. 531, 1992.
  16. P. V. Lemley, P. Amanatides, and D. C. Wright, “Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo,” Hybridoma, vol. 13, no. 5, pp. 417–421, 1994. View at Scopus
  17. P. V. Lemley and D. C. Wright, “Mice are actively immunized after passive monoclonal antibody prophylaxis and ricin toxin challenge,” Immunology, vol. 76, no. 3, pp. 511–513, 1992. View at Scopus
  18. A. Assaad, J. Hewetson, O. Parker, et al., “A ricin toxoid attenuates acute pulmonary toxicity and improves survival in rats exposed to a lethal dose of ricin aerosol,” Toxicon, vol. 33, p. 277, 1995.
  19. J. F. Hewetson, V. R. Rivera, P. V. Lemley, M. L. Pitt, D. A. Creasia, and W. L. Thompson, “A formalinized toxoid for protection of mice from inhaled ricin,” Vaccine Research, vol. 4, no. 4, pp. 179–187, 1995. View at Scopus
  20. R. B. Reisler, “Development and pre-clinical evaluation of a recombitant ricin vaccine (RVEc),” in Proceedings of the 9th ASM Biodefense and Emerging Diseases Research Meeting, Poster 210 (H), Washington, DC, USA, February 2011.
  21. J. F. Hewetson, et al., “Immune response and protection of rats and mice from ricin aerosol exposure after vaccination with deglycosylated ricin A chain,” Fundamental and Applied Toxicology, vol. 30, supplement, article 59, 1996.
  22. P. V. Lemley, D. A. Creasia, M. Plesha, D. Walters, and D. O’Neill, “Ricin sub-unit vaccination in mice and protection from challenge,” Toxicon, vol. 32, pp. 545–546, 1994.
  23. J. E. Smallshaw, A. Firan, J. R. Fulmer, S. L. Ruback, V. Ghetie, and E. S. Vitetta, “A novel recombinant vaccine which protects mice against ricin intoxication,” Vaccine, vol. 20, no. 27-28, pp. 3422–3427, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. J. E. Smallshaw, J. A. Richardson, S. Pincus, J. Schindler, and E. S. Vitetta, “Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin,” Vaccine, vol. 23, no. 39, pp. 4775–4784, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. E. S. Vitetta, J. E. Smallshaw, E. Coleman et al., “A pilot clinical trial of a recombinant ricin vaccine in normal humans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2268–2273, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. J. E. Smallshaw and E. S. Vitetta, “A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity,” Vaccine, vol. 28, no. 12, pp. 2428–2435, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. P. S. Marconescu, J. E. Smallshaw, L. M. Pop, S. L. Ruback, and E. S. Vitetta, “Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication,” Vaccine, vol. 28, no. 32, pp. 5315–5322, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. Phase 1B Study of RiVax. ClinicalTrials.gov, 2011http://www.clinicaltrials.gov/ct2/show/NCT00812071?term=rivax&rank=1.
  29. Soligenix Annual Report 2010, 2011, http://www.sec.gov/Archives/edgar/data/812796/000121390011001567/f10k2010_soligenix.htm.
  30. M. A. Olson, J. H. Carra, V. Roxas-Duncan, R. W. Wannemacher, L. A. Smith, and C. B. Millard, “Finding a new vaccine in the ricin protein fold,” Protein Engineering, Design and Selection, vol. 17, no. 4, pp. 391–397, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. J. H. Carra, R. W. Wannemacher, R. F. Tammariello et al., “Improved formulation of a recombinant ricin A-chain vaccine increases its stability and effective antigenicity,” Vaccine, vol. 25, no. 21, pp. 4149–4158, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. M. M. Meagher, J. G. Seravalli, S. T. Swanson, et al., “Process development and cGMP manufacturing of a recombinant ricin vaccine: an effective and stable recombinant ricin a-chain vaccine-RVEc,” Biotechnology Progress, vol. 27, no. 4, p. 1036, 2011. View at Publisher · View at Google Scholar
  33. D. E. McLain, T. L. Horn, C. J. Detrisac, C. Y. Lindsey, and L. A. Smith, “Progress in biological threat agent vaccine development: a repeat-dose toxicity study of a recombinant ricin toxin A-chain (rRTA) 1-33/44-198 vaccine (RVEc) in male and female New Zealand white rabbits,” International Journal of Toxicology, vol. 30, no. 2, pp. 143–152, 2011. View at Publisher · View at Google Scholar
  34. A. Porter, G. Phillips, L. Smith, et al., “Evaluation of a ricin vaccine candidate (RVEc) for human toxicity using an in vitro vascular leak assay,” Toxicon, vol. 58, no. 1, pp. 68–75, 2011.
  35. RVEc Phase I Human Clinical Trial, 2011, http://www.usamriid.army.mil/newsroom.cfm.
  36. Safety and Immunogenicity Study of Recombinant Ricin Toxin A-Chain Vaccine (RVEc), 2011, http://www.clinicaltrials.gov/ct2/show/NCT01317667?term=rvec&rank=1.
  37. L. M. Neal, J. O'Hara, R. N. Brey, and N. J. Mantis, “A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin,” Infection and Immunity, vol. 78, no. 1, pp. 552–561, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. L. M. Neal, E. A. McCarthy, C. R. Morris, and N. J. Mantis, “Vaccine-induced intestinal immunity to ricin toxin in the absence of secretory IgA,” Vaccine, vol. 29, no. 4, pp. 681–689, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Prigent, L. Panigai, P. Lamourette et al., “Neutralising antibodies against Ricin Toxin,” Plos ONE, vol. 6, no. 5, Article ID e20166, 2011. View at Publisher · View at Google Scholar
  40. B. Stechmann, S. K. Bai, E. Gobbo et al., “Inhibition of retrograde transport protects mice from lethal ricin challenge,” Cell, vol. 141, no. 2, pp. 231–242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. P. G. Wahome, J. D. Robertus, and N. J. Mantis, “Small-molecule inhibitors of ricin and shiga toxins,” Current Topics in Microbiology and Immunology, vol. 357, pp. 179–207, 2012.
  42. V. St. Georgiev, “National institute of allergy and infectious diseases,” in Impact on Global Health, vol. 2, pp. 274–277, Humana Press, New York, NY, USA, 2009.